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ABSTRACT: A 60-year-old woman wilh plaque-type psoriasis
of 30 years' duration was treated with etretinate. The lesion
resolved while the patient was on the drug and continued
to resolve after she had discontinued therapy. The contin-
uation of resolution after the patient had discontinued the
drug is prohahly due to its long half-life.
Since the original descriptions of porokeratosis in
1893 by Mibelli' and Respighi,- various therapeutic
modalities have been sought. Excision, irradiation, car-
bon dioxide snow, silver nitrate cautery, and currettage
have been tried as well as UV light, roentgen therapy,
keratoiytics, thyroid supplements, topical and intrale-
sional steroids, 5% FU ointment, and vitamin A
(300,000 U every day for 12 weeks)."""* Recently, two
reports have appeared in the literature concerning re-
missions of porokeratosis of Mibelli in response to
aromatic retinoid therapy (RO 109359)."• '"We have had
the opportunity to follow a patient with localized
porokeratosis of Mibelli of 10 years' duration who, when
treated with retinoid therapy (RO 109359) for psoriasis,
experienced slow lesion resolution. To our knowledge,
this is the third reported case in the literature.
Case Report
A bO-year-old white woman had plaque-type psoriasis ol 30
years' duration. For the past 10 years, she bas been followed at
the University ol" Michigan Dermatology Department for
psoriasis; during this time, she was noted to have an area of
classic ])orokeratosis of Mibelli on tbe Inner aspect ol' her left
leg (Fig. 1). Early treatment for her psoriasis included modified
Goeckerman tberapies, PUVA, and methotrexate, none oi
whicb caused any changes in her lesion of porokeratosis. Be-
cause of eariy changes of portal tibrosis on a liver biopsy,
methotrexate therapy was discontinued. After a 4-week wasb-
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out period, she was started on an experimental protocol with
etretinate for psoriasis. Because of its incidental nature and
classical appearance, no biopsy was performed on the lesion
of porokeratosis.
In September 19»1, she began 1 mg/kg/day (80 mg/day) tor
a period oi 2 months. Her dose was then dropped to 50
mg/day (0.6 mg/kg/day) as per protocol. When the patient was
seen after 5 months of' therapy, the area of porokeratosis was
covered with a red erosion and she complained ot pruritus (Fig.
2). In March 1982, tbe drug was discontinued for a 3-month
FIC. 1.
etretinate.
Classic porokeratosis of Mibelli before treatment witb
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f\i.. 2. Erylheniri .intl erosions at site of porokeratosis ol
MJbt'lli afler 5 months of therapy.
Wiish-out period. The lesion continued to show increasing ery-
lheni.1, induration, and pruritus. In June 1992, the drug was
resumed at 1 mg/lcg/day for 2 months and then decreased to
O.fa mg/kg/day. Because of a granulation tissue response
around her toenails. she elected to discontinue etretinate
therapy in September 1982. The lesion at that time measured 2
X 2'/2 cm and was f|uite erythematous with mild induration at
the sites of erythema. The initial scaling noted at this site when
the intl.immation began hod resolved.
The patient was seen again in lollow-up in January 1983.
There was no evidence ot' the |H>rokeratosis ot Mibelli (Fig. 3).
Mild scarring was seen at the prior lesion site. The area has
remained clear for the past 17 months.
Discussion
Two recent reports indicate improvement of
IKjrokeratosis with etretinate therapy. Bundtno and Fina"
report the use of RO 109359 in widespread
porokeratosis ol Mibelli using dosages of 75 mg/day for
10 days, then 50 mg/day for 3 weeks. The drug caused
general improvement in their study. One patient com-
plained of pruritus at the site of lesions once therapy was
started. The first changes occurred after a week, at which
time the lesions became inflamed and initial desquama-
tion appeared. During this time, some of the hyper-
keratosis crumbled away. After another week of therapy.
Frc 3. Resolution of porokeratosis of Mibelli with mild scarring
at prior lesion site.
the rim became less evident. Better results were noted in
lesions on the (ace. thighs, and arms. In a second case,
the hyperkeratotic scales disappeared but the lesion re-
mained indurated. Some lesions resolved with residua!
hyperpigmentation but no scar. A daily dose of 25
mg/day kept most areas clear with only a few lesions
relapsing, while suspension of treatment allowed more
recurrence after 3-4 weeks. Bundino and Fina pos-
tulated that etretinate had a morbistatic action, since ul-
trastructural changes peculiar of porokeratosis of Mibelli
(vaculated or dyskeratotic cells) could still be found in
clinically improved lesions and the lesions clinically re-
curred after the suspension of treatment.
Pehamberger and Konrad'" treated a fifteen-year-old
white boy with linear porokeratosis of Mibelli with
etretinate at 1 mg/kg/day for 7 weeks, during which time
the lesions decreased in thickness and thinning of the
elevated ridges without any pronounced inflammatory
reaction was noted. The drug was decreased to 0.5 mg/
kg/day for 5 weeks, at which time only residual hyper-
pigmentation remained visible. No mention is made in
the report of long-term remission if the drug was
discontinued.
Our present case differs from previously reported
cases in several ways. First, our case was a localized
form of porokeratosis of Mibelli. Those cases reported
previously were of a disseminated or a linear variety.
Second, it took 20 weeks of therapy before erythema
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was first noted at the lesion site. This inflammatory reac-
tion then persisted for many months before gradual reso-
lution of the lesion occurred, This is a much slower
clearing time than that reported by either Bundino or
Pehamberger (4 weeks and 7 weeks, respectively); how-
ever, the same sequence of clinical improvement
seemed to follow. Pruritus, decreased hyperkeratosis,
and inflammation occurred in all cases.
Third, our patient's porokeratosis continued to resolve
during periods when she was off the drug. Further, the
site has remained clear tor 17 months off therapy. This
differs from the rapid recurrence reported by Bundino
when etretinate therapy was discontinued. Spontaneous
resolution of the porokeratosis of Mibelli cannot be ruled
out, yet the frequency of spontaneous resolution of the
porokeratosis of Mibelli cannot be determined by a re-
view of the literature. We believe that the continuation
of resolution while off the drug can be attributed to
etretinate's long half-life of elimination, especially in our
[)atient, who was on chronic long-term therapy. Follow-
ing cessation ol long-term therapy, an individual may get
significant drug levels in plasma from some deep storage
compartment, such as the liver." This would explain
why the site on our patient continued to clear while off
Iherapy.
The histogenesis of porokeratosis has been attributed
to a clone of abnormal epidermal cells located at the
base of the parakeratotic column, wbich forms the cor-
noid lamella.'- Etretinate's effect on porokeratosis prob-
ably stems from its action as "a general regulator of
epidermal phenomena related to dysfunction of epider-
mal cell differentiation, keratin synthesis, and desqua-
mation of corneocytes." '̂
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